https://www.polity.org.za
Deepening Democracy through Access to Information
Home / News / South African News RSS ← Back
Africa|Health|Lifting|Safety|Screening|Products
Africa|Health|Lifting|Safety|Screening|Products
africa|health|lifting|safety|screening|products
Close

Email this article

separate emails by commas, maximum limit of 4 addresses

Sponsored by

Close

Article Enquiry

SAHPRA recommends lifting suspension of J&J vaccine roll-out, with conditions

Close

Embed Video

SAHPRA recommends lifting suspension of J&J vaccine roll-out, with conditions

SAHPRA recommends lifting suspension of J&J vaccine roll-out, with conditions
Photo by Reuters

19th April 2021

By: Thabi Madiba
Creamer Media Senior Research Assistant and Reporter

ARTICLE ENQUIRY      SAVE THIS ARTICLE      EMAIL THIS ARTICLE

Font size: -+

The South African Health Products Regulatory Authority (SAHPRA) has recommended that the pause of the Sisonke vaccine trial study using the Johnson & Johnson Covid-19 vaccine be lifted, provided that specific conditions are met.

The US, South Africa and the European Union temporarily stopped the rollout of the Johnson & Johnson jab, after six cases of rare blood clotting were reported in the US.

Advertisement

SAHPRA has engaged with the Sisonke Phase 3B Implementation Study team and Janssen Pharmaceutica, which is owned by Johnson & Johnson, to discuss the safety data reported from the Sisonke study.

“These conditions include, but are not limited to, strengthened screening and monitoring of participants who are at high risk of a blood clotting disorder. In addition, measures are to be implemented to ensure the safe management of any participants who develop vaccine-induced thrombosis and thrombocytopenia. The participant information sheets and informed consent forms will be updated to include the newly identified adverse events,” said SAHPRA.

Advertisement

The authority has highlighted that participants in the Sisonke study will be informed about the possible risks of developing a blood clotting disorder after vaccination and will also be advised to seek immediate medical assistance if they develop early signs and symptoms associated with blood clots or low platelet counts.

It added that the study team will submit the required updated documents, procedures and study arrangements to SAHPRA for approval.

SAHPRA said the resumption of the Sisonke Phase 3B Implementation Study will also require approval from the relevant Research Ethics Committees.

EMAIL THIS ARTICLE      SAVE THIS ARTICLE ARTICLE ENQUIRY

To subscribe email subscriptions@creamermedia.co.za or click here
To advertise email advertising@creamermedia.co.za or click here

Comment Guidelines

About

Polity.org.za is a product of Creamer Media.
www.creamermedia.co.za

Other Creamer Media Products include:
Engineering News
Mining Weekly
Research Channel Africa

Read more

Subscriptions

We offer a variety of subscriptions to our Magazine, Website, PDF Reports and our photo library.

Subscriptions are available via the Creamer Media Store.

View store

Advertise

Advertising on Polity.org.za is an effective way to build and consolidate a company's profile among clients and prospective clients. Email advertising@creamermedia.co.za

View options
Free daily email newsletter Register Now